Herceptin is new option in advanced HER2-positive gastric cancer, say experts
This article was originally published in Scrip
Roche's (Genentech) HER2-targeted breast cancer drug Herceptin (trastuzumab) was recommended by experts as a new option in HER2-positive advanced gastric cancer after it prolonged median overall survival by almost three months when added to chemotherapy in the pivotal first-line ToGA trial, the results of which were presented at the ASCO meeting in Orlando this week.
You may also be interested in...
The development of drugs to prevent cancer has lagged far behind the development of drugs, such as the statins, to prevent cardiovascular disease. But consideration of new, "personalised" clinical trial designs and an improved understanding of the biology of precancers, as well as new agents which target their molecular abnormalities, may make the field a more promising investment, says Malini Guha.
Janssen-Cilag's (Johnson & Johnson) injectable drug Xeplion (paliperidone palmitate) has been recommended for European approval by the CHMP for the treatment of schizophrenia.
The CHMP has recommended for European approval Pfizer's Xiapex (collagenase clostridium histolyticum) for the treatment of Dupuytren’s contracture, a potentially debilitating hand condition.